Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel





Microbial Safety of Platelet Concentrates: updates and outlook

Oleg Krut

Microbial Safety Section Department of Microbiology Paul-Ehrlich-Institut

www.pei.de



×

Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel





- Marketing authorisation
- Licensing of clinical trials
- OMCL batch release

Platelet concentrates are the most frequent source of the transfusion related septic reactions



Storage at: 4°C <-25°C 22°C Permissive temperature!

Measures to prevent bacterial contamination

- donor deferral criteria of risk patients
- effective skin disinfection procedures
- aseptic blood collection and processing
- utilization of sterile equipment
- predonation sampling
- leukocyte depletion



How frequent are septic episodes after transfusion of PCs?

PEI hemovigilance report 2015

Transfusion-related bacterial infections (ppm)	2012	2013	2014	2015
RBCs	0,46	0,49	0,75	0,27
PCs	5,82	3,99	8,03	1,97
Plasma	0,00	0,00	0,00	0,00



Microbiological control strategies for TCs are not harmonized among EU member states

EC Directives 2002/98/EC and 2004/33/EC

differently implemented at national level



Created with mapchart.net ©



Risk mitigation strategies: overview





Risk mitigation strategies: overview



Early sampling sreening strategy is suboptimal for detection of microbial contaminants





State of the Art I: growth based Methods



Late sampling (>30-48 h after donation) Large Sample Volume > 8 ml / bottle Both aerobic and anaerobic bottle Quarantine before and during testing (6h)

> 90% Reduction of septic reactions
(McDonald 2017 NHSBT)

- false positive rate (anaerobic)
- "negative to date" concept
- expenses



Risk mitigation strategies: overview





State of the art II: Pathogen reduction systems





TC + Amotosalen + UV A
$$\Box$$
 DNA \Rightarrow InactivationTC + Riboflavine + UV $crosslinking$ $viability for bTC ++ UVC $viability for b$$

 \Rightarrow Inactivation i.e. (several logs) reduction of viability for bacteria, fungi and viruses



State of the art II: Pathogen reduction systems



Jutzi et al 2018



Is it worth to implement microbial control strategy?

Reported incidence about 5 ppm = 0.0005%



=> These figures are usually significantly higher than hemovigilance reports



Possible reasons for underreporting of septical episodes after PC transfusion

- passive vigilance report only 10-20% from total incidence (Jacobs et al)
- only 10% of reports have verified a root cause of infection (PEI Data)
- concomitant effective antibiotic treatment
- only acute septic (pyrogenic) reactions (till 4h after transfusion)

Transfusion of contaminated PCs is frequently asymptomatic



Hong et al 2016



Critical Care

ca. 19000 Patients

Aubron et al. Critical Care (2017) 21:2

DOI 10.1186/s13054-016-1593-x

Conclusions: After adjustment for confounders, including patient severity and other blood components, platelet transfusion was independently associated with ICU-acquired infection.



Summary

- risk mitigation for bacterial contamination of platelet concentrates can be implemented through screening by growth-based methods or pathogen reduction technologies
- late (>36 h after donation) sampling strategy seem to be more effective than early sampling
- whenever possible the microbiological control strategy should be implemented, since frequency of transfusion septic incidents might be much higher as hemovigilance data suggest
- necessity of harmonization of the microbiological strategies among EU member states

Bundesinstitu und biomedizi



www.pei.de

Health is our focus

Thank you for your attention !

Section Microbial Safety: Ingo Spreitzer, Marcel Prax, Holger Lößner, Oliver Karo, Birgit Blissenbach, Anja Schneider, Marie Anders-Mauer, Bjorn Becker, Philipp Windecker



Growth kinetics K. pneumoniae Strains

Low titer spiking (ca. 30 CFU / Unit) of PCs from different donors Colony count determination over time (22.5°C, agitation)



relevant differences between strains of the same bacterial species